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Simple Summary: Currently, platinum-based neoadjuvant chemotherapy (NAC) is becoming a
standard treatment for use in patients with muscle-invasive bladder cancer. However, comparisons
of oncologic outcomes for the two most commonly used NAC regimens, ddMVAC (dose-dense
methotrexate, vinblastine, doxorubicin, and cisplatin) and GC (gemcitabine and cisplatin), are
controversial. We sought to compare the oncologic outcomes of these two regimens via a systematic
review and meta-analysis of all the available studies published to date. Through this, we aimed to
provide evidence on the optimal NAC regimen for use in muscle-invasive bladder cancer.
Abstract: Platinum-based neoadjuvant chemotherapy (NAC) is widely used for treating muscle-
invasive bladder cancer (MIBC). A systematic review was performed following PRISMA guidelines.
PubMed, Embase, and the Cochrane Library were searched up to December 2020. We conducted a
meta-analysis to compare the oncologic outcomes of ddMVAC (dose-dense methotrexate, vinblastine,
doxorubicin, and cisplatin) and GC (gemcitabine and cisplatin), which are the most widely used
NAC regimens. Endpoints included pathologic complete response (pCR), pathologic downstag-
ing (pDS), overall survival (OS), and cancer-specific survival (CSS). Five studies, with a total of
1206 patients, were included for meta-analysis. pCR was observed in 35.2% of the ddMVAC arm
and in 25.1% of the GC arm, and pCR was significantly higher in ddMVAC than in GC (odds ratio
(OR), 1.45; 95% confidence interval (CI), 1.11–1.89; p = 0.006). There was no significant difference
in pDS (OR, 1.37; CI, 0.84–2.21; p = 0.20). OS was significantly higher in ddMVAC than in GC
(hazard ratio, 2.16; CI, 1.42–3.29; p = 0.0004). Only one study reported CSS outcomes. The results
of this analysis indicate that ddMVAC is superior to GC in terms of pCR and OS, suggesting that
ddMVAC is more effective than GC in NAC for MIBC. However, this should be interpreted with
caution because of the inherent limitations of retrospective studies.
Keywords: bladder cancer; neoadjuvant chemotherapy; gemcitabine; cisplatin; dose-dense MVAC
1. Introduction
Bladder cancer manifests in most cases as a non-muscle invasive disease and requires
only local treatment. Notwithstanding, approximately 25% of bladder cancers invade the
muscle layers and 5% have metastatic disease [1]. Radical cystectomy with bilateral pelvic
lymph node dissection is a standard local treatment for non-metastatic muscle-invasive
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bladder cancer (MIBC). However, a large proportion of MIBC patients experience relapse
and eventually die after radical cystectomy and pelvic lymph node dissection [2]. Lo-
cal recurrence rates range from 30% to 54%, and distant relapses occur in up to 50% of
cases [3–6]. Therefore, perioperative chemotherapy, such as adjuvant or neoadjuvant ther-
apy, is used for MIBC. In randomized clinical trials (RCTs) and meta-analyses evaluating
the clinical outcomes of neoadjuvant chemotherapy (NAC) [7–9], an increase in overall
survival (OS) by 5–6% for NAC, compared with radical cystectomy alone, was reported in
MIBC patients [10,11].
Various NAC regimens have been tested over the years. The American Urological
Association and the European Urological Association guidelines currently recommend
platinum-based NAC [3,12]. The most studied platinum-based NACs include methotrexate,
vinblastine, doxorubicin, and cisplatin (MVAC) regimens, and gemcitabine and cisplatin
(GC) regimens. In 2003, the Southwest Oncology Group-8710 RCT demonstrated that
the use of an MVAC regimen for NAC improved survival and pathologic downstaging
(pDS) [10]. Another RCT reported that the oncologic outcomes of GC and MVAC regi-
mens were similar; however, the former had a better toxicity profile [13]. One study was
conducted on dose-dense MVAC (ddMVAC) plus human granulocyte colony-stimulating
factor to supplement the toxicity of MVAC, and a phase 2 trial showed that NAC based on
a ddMVAC regimen was well tolerated and safe and that the oncologic results were similar
to those of standard regimens [14,15]. Based on these favorable results, ddMVAC and GC
have been widely used in NAC in recent years, and the latest National Comprehensive
Cancer Network guidelines recommend these two regimens for NAC [12].
However, few studies have compared the two regimens, and a recent phase 3 RCT
study did not report long-term follow-up results [16]. Therefore, analyzing studies that
have compared ddMVAC and GC regimens for NAC is essential. This systematic review
and meta-analysis compares the clinical outcomes of ddMVAC and GC, to determine which
is optimal in NAC for patients with MIBC.
2. Materials and Methods
2.1. Search Strategy and Data Extraction
This systematic review was registered with PROSPERO (CRD42020196422) and com-
plied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (http://www.prisma-statement.org/ (assessed on 31 May 2021)) [17].
Relevant studies that compared two NAC regimens (ddMVAC and GC) for MIBC were
searched up to December 2020 using PubMed, Ovid-EMBASE, the Cochrane Central Reg-
ister of Controlled Trials, and the following Medical Subject Headings terms: “bladder
cancer”, “bladder carcinoma”, “neoadjuvant”, “MVAC”, “gemcitabine”, “cisplatin”, “regi-
men”, and relevant variations of these terms. The search was restricted to human studies
published in English. Two reviewers (DYC and JWK) independently screened the titles
and abstracts of the retrieved articles based on the inclusion criteria. Any discrepancies
in the data extracted between the two reviewers were resolved by a third reviewer (KSC).
The study was exempt from the approval of an ethics committee or institutional review
board because it was a systematic review and meta-analysis.
2.2. Inclusion Criteria and Study Eligibility
The eligibility of each study was evaluated taking into account participants, inter-
ventions, comparators, outcomes, and study design approach (PICOS): [18] Participants,
patients with biopsy-proven MIBC who intended to undergo radical cystectomy and
patients who underwent systemic NAC; Interventions, MIBC patients who underwent
systemic NAC using ddMVAC; Comparators, MIBC patients who underwent systemic
NAC using GC with the same characteristics; Outcomes, comparison of oncologic outcomes
(pathologic complete response (pCR), pDS, OS, and cancer-specific survival (CSS)); and
Study design, no restrictions on research design, with both randomized controlled studies
and nonrandomized observational studies included for analysis.
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The primary endpoint was pCR, the secondary endpoint was pDS, and the tertiary
endpoints were OS and CSS. Both pCR and pDS were determined by pathological exami-
nation after surgery; pDS was defined as decreased pathologic stage compared with the
preoperative clinical stage, or downstaging to non-muscle-invasive disease. CSS and OS
were defined as the time from the date of surgery to the date of cancer-specific mortality
and death from any cause, respectively.
2.3. Quality Assessment
A quality assessment was independently performed by two reviewers (DYC and
DHK) using the criteria provided by the Cochrane risk-of-bias tool and the Newcastle–
Ottawa scale [19,20]. The Cochrane risk-of-bias tool for quality assessments of RCTs was
recommended by the Cochrane Handbook for Systematic Reviews of Interventions and
includes the following risk-of-bias domains: (1) random sequence generation, (2) allocation
concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment,
(5) incomplete outcome data, (6) selective reporting, and (7) other potential biases. Each
item was further divided into three categories based on the risk of bias: high, low, and
unknown. The three major assessment categories of the Newcastle–Ottawa scale were
selection, comparability, and exposure. Studies can be rated up to nine stars. A final score
of six stars or more indicates high quality.
2.4. Statistical Analysis
Odds ratios (ORs), weighted mean differences, and 95% confidence intervals (CIs) were
calculated for dichotomous variables (pCR and pDS). The effects of NAC on OS and CSS
were measured using hazard ratios (HRs). Log HR values were obtained from trials reporting
HR estimates and CIs, and the standard errors of log HR were calculated using CIs. The
effects of ddMVAC and GC on OS and CSS were assessed by pooled HRs and 95% CIs [21].
Between-study heterogeneity was assessed using chi-square and I2 tests. A Cochran
Q statistic p-value < 0.05 or I2 statistic >50% was used to indicate statistically significant
heterogeneity between trials [22].
Based on the degree of heterogeneity, either a random-effects or fixed-effects model
was applied to calculate summary measures. Data were analyzed using a random-effects
model, provided there was evidence of heterogeneity [23]. In the event that at least 10 stud-
ies that investigated a particular outcome were included, funnel plots were to be used
to assess small effects; however, fewer than 10 studies qualified for this review [24]. The
meta-analysis was conducted using Review Manager version 5.3 (RevMan, Copenhagen:
The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark, 2013).
3. Results
3.1. Systematic Review Process
A study selection flowchart according to PRISMA guidelines is presented in Figure 1.
The initial database search identified 3317 studies (940 in PubMed, 2121 in OVID-EMBASE,
and 256 in Cochran library). Of these, 1457 studies remained for review after removing
duplicates. Fifteen articles were excluded after screening the titles and abstracts. Full-text
articles were analyzed based on pre-established inclusion criteria. Five studies [16,25–28],
with a total of 1206 patients, were included in the final analysis (Table 1). One study was an
RCT, while the others were retrospective case-control studies. Three studies were conducted
in the United States, one in the Netherlands, and one in France. All trials enrolled patients
diagnosed with MIBC who had undergone either GC or ddMVAC as NAC.
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Figure 1. Study selection flowchart according to the Preferred Reporting Items for Systematic Reviews
and Meta-analysis guidelines.
3.2. Quality Assessment
The results of the quality assessment based on the Cochrane risk-of-bias tool are
shown in Table 2A. In the RCT, there was a bias of being an unblinded study. Since the
schedule of chemotherapy was different, this seemed to be an unavoidable option. The
results of the quality assessment using the Newcastle–Ottawa scale for the nonrandomized
studies are shown in Table 2B. Four studies received a score of seven points, indicating
high quality.
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Table 2. Results of quality assessment using the Cochrane risk-of-bias tool and Newcastle–Ottawa scale.
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3.3. Pathologic Complete Response Rate
Pathologic CR was observed in 35.2% (161/458) of the ddMVAC arm and in 25.1%
(188/748) of the GC arm (p < 0.001 by Chi-square test) (Table 1). We conducted two analyses,
as shown in Figure 2: one with four observational studies, and one with four observational
studies and one RCT. In the former analysis (observational studies only), the pCR rate
was not significantly different between the two regimens (OR = 1.48; 95% CI, 0.87–2.52;
p = 0.15), and heterogeneity was found across studies (I2 statistic, 53%; Cochran Q statistic,
p = 0.09). In the latter analysis (all studies), the pCR rate was higher in the ddMVAC group
(OR = 1.45; 95% CI, 1.11–1.89; p = 0.006), and no between-study heterogeneity (I2 statistic,
43%; Cochran Q statistic, p = 0.14) was found.
Figure 2. Forest plots of pathologic complete response rates. (A): Observational studies only. (B): All studies.
3.4. Pathologic Downstaging Rate
The pDS rates of the ddMVAC and GC regimens were 57.2% (262/458) and 46.5%
(348/748), respectively (p < 0.001 by Chi-square test) (Table 1). Two analyses were
performed as described in item 3.3 (Figure 3). In the former analysis (observational
studies only), there were no significant differences in pDS rate between the two regi-
mens (OR = 1.23; 95% CI, 0.62–2.41; p = 0.55), and there was heterogeneity across studies
(I2 statistic, 76%; Cochran Q statistic, p = 0.005). The latter analysis (all studies) revealed no
significant differences between the two regimens (OR = 1.37; 95% CI, 0.84–2.21; p = 0.20),
and there was some between-study heterogeneity (I2 statistic, 70%; Cochran Q statistic,
p = 0.01).
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Figure 3. Forest plots of pathologic downstaging rates. (A): Observational studies only. (B): All studies.
3.5. Overall Survival and Cancer-Specific Survival
OS and CSS outcomes between the two regimens are shown in Figure 4. Two studies
were included in the OS analysis, and the results indicated that OS was higher in the
ddMVAC group versus the GC group (overall HR, 2.16; 95% CI, 1.42–3.29; p = 0.0004;
I2 statistic, 0%). Only one study reported CSS outcomes (HR, 2.31; 95% CI, 1.29–4.13;
p = 0.005).
Figure 4. Forest plots of survival outcomes. (A): Overall survival. (B): Cancer-specific survival.
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4. Discussion
Since the Southwest Oncology Group reported a positive effect of NAC using MVAC
for MIBC in 2003 [10], NAC before radical cystectomy and pelvic lymph node dissection
has been used as the standard treatment for MIBC. A few years later, GC and ddMVAC
regimens were established as the standard NAC treatments, with low morbidity, low
toxicity, and good oncologic outcomes [12–14,29].
Various NAC regimens have been implemented in the past few years, and clinical
trials on immune-oncology agents are underway [30–32]. Although studies on novel NAC
treatments are ongoing, large-scale RCTs and long-term follow-up studies are lacking.
Therefore, finding and evaluating optimal platinum-based NAC regimens for cisplatin-
eligible MIBC patients is crucial.
A phase 3 RCT reported that ddMVAC caused more severe asthenia and gastroin-
testinal side effects than GC in perioperative chemotherapy, but elicited a significantly
higher local control rate (pCR, pDR, or organ-confined tumors) in MICB patients [16].
However, this RCT has not yet reported long-term oncologic outcomes, such as OS, CSS,
and progression-free survival [16]. In this respect, the present study helped identify an op-
timal platinum-based NAC regimen. Our meta-analysis demonstrated that ddMVAC was
superior to GC with regards to pCR and OS. In addition, considering that there was no de-
tectable difference in toxicity profiles and tolerability between ddMVAC and GC [14,15,33],
ddMVAC should be considered the standard of care for MIBC [14,15,33].
Our analysis of two retrospective studies showed that OS was better in the ddMVAC
group. However, insufficient data on the long-term comparative oncological outcomes,
such as OS, CSS, and progression-free survival, between ddMVAC and GC is a limitation.
It is expected that an answer will be obtained through follow-up results from ongoing
phase 3 RCTs. Meanwhile, we believe that the long-term oncological results will be better
in the ddMVAC arm because ddMVAC is superior to GC regarding pCR. Previous studies
reported that the prognosis in patients with pCR after NAC was good. Petrelli et al.
conducted a meta-analysis to determine whether pCR after NAC was associated with an
improved outcome in MIBC [29] and found that patients with pCR after NAC and radical
cystectomy had a 55% lower risk of mortality (relative risk (RR), 0.45; 95% CI, 0.36–0.56;
p < 0.00001) and an 81% lower risk of recurrence, compared with patients with pathologic
residual disease (RR, 0.19; 95% CI, 0.09–0.39; p < 0.00001). A recent cohort study enrolled
1553 patients (314 with pCR and 1239 with pathologic residual disease) and found that
patients with pCR had better OS than those without pCR and that the average HR for
pathologic residual disease versus pCR was 4.56 (95% CI, 3.34–6.26) [34], suggesting that
pCR following NAC improves survival in MIBC.
Nevertheless, there is controversy regarding the optimal number of cycles of ddMVAC
in a neoadjuvant setting. No studies have compared the optimal cycles of ddMVAC. The
results of four retrospective studies showed that pCR and pDS were 21.0–41.3% and
37.5–69.0%, respectively, after three to four cycles of ddMVAC [25–28] whereas, the RCT
found that pCR and pDS were 42.2% and 63.3%, respectively, after a six-cycle course [16].
However, a six-cycle course may increase side effects, potentially delaying surgery. In
addition, the longer the time period between NAC and radical cystectomy, the more the
cancer progresses [35]. Therefore, improvement in pCR and pDS after six cycles of ddMVAC
does not necessarily improve survival, and further research is needed to determine the
ideal number of cycles of ddMVAC.
This study has limitations. First, the number of selected studies was small because
few studies in the literature have compared the two regimens. Second, four studies were
retrospective and were, therefore, prone to biases related to treatment allocation, grouping,
and data collection. Notwithstanding, the retrospective studies included in our study
were of high quality when evaluated using the Newcastle–Ottawa scale. In addition, there
were no studies showing significant differences between the two groups based on a table
comparing the baseline characteristics of the ddMVAC group and the GC group in each
study. Third, the results of OS and CSS should be interpreted with caution because of the
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small number of long-term follow-up studies. Despite these limitations, this study is the
first meta-analysis to compare oncologic outcomes between ddMVAC and GC for NAC.
We provide evidence that ddMVAC may be a better NAC treatment than GC in patients
with MIBC. Additional well-designed RCTs are necessary to confirm our conclusion.
Currently, studies on NAC responses in patients with variant histology or expression
of specific biomarkers are in progress [36–38]. For instance, Miron et al. has reported
that patients with mutations in ATM, RB1, or FANCC had a better response to NAC and
improved long-term survival [37]. As mentioned earlier, NAC studies on immunotherapy
are underway. In NAC for MIBC using immunotherapy, studies including ABACUS trial
(atezolizumab) [32,39] and PURE-01 (pembrolizumab) [30] have been conducted. Although
they have not yet published a large-scale phase 3 RCT study, they have shown good
results in preliminary studies. In these studies, a patient’s pathologic response was found
to be related to biomarker results. Although large-scale studies should be published in
the future, these immunotherapy results may serve as the basis for individual, patient-
specific treatments.
5. Conclusions
In our meta-analysis, ddMVAC was superior to GC with regards to pCR and OS,
suggesting that ddMVAC is more effective than GC in NAC for MIBC. However, this
finding should be interpreted with caution because of the inherent limitations of retrospec-
tive studies. Large-scale RCTs and long-term follow-up studies are warranted to validate
these outcomes.
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